Trial · NCT02361346
Adverse events1,881
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,881
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part 1: Cohort 1: 5 Micrograms/Kilograms/Dose/Day | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: Cohort 2: 10 mcg/kg/Dose/Day | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: Cohort 3: 20 mcg/kg/Dose/Day | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: Cohort 4: 50 mcg/kg/Dose/Day | 2 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: Cohort 5: 100 mcg/kg/Dose/Day | 1 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: Cohort 6: 75 mcg/kg/Dose/Day | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2: Cohort 7- MTD Expansion Cohort (50 or 75 mcg/kg/Dose) | 0 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 3: All MT-3724 Treated Participants | 0 | 11 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 4: All MT-3724 Treated Participants | 0 | 0 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: Cohort 1: 5 Micrograms/Kilograms/Dose/Day | 0 | 3 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: Cohort 2: 10 mcg/kg/Dose/Day | 0 | 3 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: Cohort 3: 20 mcg/kg/Dose/Day | 0 | 3 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: Cohort 4: 50 mcg/kg/Dose/Day | 1 | 4 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: Cohort 5: 100 mcg/kg/Dose/Day | 0 | 2 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: Cohort 6: 75 mcg/kg/Dose/Day | 1 | 6 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 2: Cohort 7- MTD Expansion Cohort (50 or 75 mcg/kg/Dose) | 0 | 6 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 3: All MT-3724 Treated Participants | 0 | 11 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 4: All MT-3724 Treated Participants | 0 | 0 | |
| other | Leukopenia | Blood and lymphatic system disorders | Part 1: Cohort 1: 5 Micrograms/Kilograms/Dose/Day | 1 | 3 | |
| other | Leukopenia | Blood and lymphatic system disorders | Part 1: Cohort 2: 10 mcg/kg/Dose/Day | 0 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02361346/events